Wie advies wilt over hoe het microbioom te verbeteren zou contact op kunnen nemen met deze website: Www.microbiome-Center.nl Voor zowel artsen als individuele burgers staat een groep van artsen en wetenschappers klaar om u een persoonlijk advies te geven

Lees ook artikelen over probiotica bij operatie van darmkanker en andere vormen van kanker in overzicht probiotica en synbiotica.

22 juli 2019: Bron: Journal of Cancer

Wanneer maagkankerpatienten die een gedeeltelijke operatie van hun maag moeten ondergaan wegens kanker na de operatie een mix van probiotica gebruiken (Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis and Bacillus cereus) gedurende een week dan ervaren zij minder ernstige lichamelijke klachten en herstelt de darmflora sneller en komt de voedingsverwerking sneller op gang. Dit blijkt uit een placebo gecontroleerde gerandomiseerde studie bij totaal 100 patienten met maagkanker. Geen van de patienten heeft naast de operatie bestraling of chemo gekregen in deze studie om de resultaten zuiver te houden, zo schrijven de onderzoekers.

Hier een grafiek van de deelnemers bij de start van de studie:

Table 1

Baseline patient demographics and characteristics. AC, cancer patients after gastrectomy and treatment without probiotic combination; ACP, cancer patients after gastrectomy and treatment with probiotic combination.

Variable	AC Group (N=50)	ACP Group (N=50)	P value
Percentage of total enrollment, No. (%)	50 (50.00)	50 (50.00)	/
Male: female, n:n (%:%)	41:9 (82.00:18:00)	43:7 (86.00:14.00)	0.585
Age, y	64.00 (56.75-69.25)	60.00 (51.75-67.25)	0.122
Tumor category, No. (%)
T0	0 (0.00)	1 (2.00)	0.510
T1	6 (12.00)	3 (6.00)
T2	5 (10.00)	3 (6.00)
T3	9 (18.00)	7 (14.00)
T4	30 (60.00)	36 (72.00)
Node category, No. (%)
N0	16 (32.00)	16 (32.00)	0.772
N1	23 (46.00)	22 (44.00)
N2	6 (12.00)	9 (18.00)
N3	5 (10.00)	3 (6.00)
M category, No. (%)
M0	50 (100.00)	50 (100.00)	/
TNM category, No. (%)
TNM1	9 (18.00)	6 (12.00)	0.347
TNM2	13 (26.00)	9(18.00)
TNM3	28 (54.00)	35 (70.00)

Open in a separate window

Uit bloedonderzoek kwamen de volgende resultaten aldus de onderzoekers:

We vonden dat de probiotica combinatie de leukocyten ontstekingswaarden sterk verminderde (102.7% vs. 162.8%, p < 0.0001), en sterk de lymphocyten immuno waarden verbeterde (80.31% vs. 59.79%, p < 0.001), ook de voeginswaarde van albumine verbeterde (88.75% vs. 84.38%, p < 0.05) en de totale eiwitwaarde (88.63% vs. 82.49%, p < 0.01) (Fig. (Fig.1)1) in vergelijking met de placebogroep.

Nog mooier: onze data tonen aan dat de probiotica aanwijsbaar de waarden van belangrijke waarden heeft hersteld naar normaal in vergelijking met de placebo controlegroep waar de belangrijkste waarden nog lang niet waren hersteld: zoals de leukocyten (92% vs. 82%), centrale granulocyten (92% vs. 40%), central granulocyte ratio (60% vs. 34%), lymphocyten (14% vs. 2%) en lymphocyten ratio (32% vs. 8%), erythrocyten (14% vs. 2%), creatinine (72% vs. 54%) en chlorinum (80% vs. 64%) (Table (Table22).

Table 2

Rate of people restoring to normal range. AC, cancer patients after gastrectomy and treatment without probiotic combination; ACP, cancer patients after gastrectomy and treatment with probiotic combination.

Index	Normal standards	Groups	People within normal range	Total people	Rate of people within normal range (%)
Leukocyte	(3.5-9.5)×10⁹ cells /L	AC	41	50	82
Leukocyte	(3.5-9.5)×10⁹ cells /L	ACP	46	50	92
Central granulocyte	(2-7)× 10⁹ cells /L	AC	20	50	40
Central granulocyte	(2-7)× 10⁹ cells /L	ACP	46	50	92
Central granulocyte ratio	(40-75)%	AC	17	50	34
Central granulocyte ratio	(40-75)%	ACP	30	50	60
Lymphocyte	(1.5-4)× 10⁹ cells /L	AC	1	50	2
Lymphocyte	(1.5-4)× 10⁹ cells /L	ACP	7	50	14
Lymphocyte ratio	(20-50)%	AC	4	50	8
Lymphocyte ratio	(20-50)%	ACP	16	50	32
Hemoglobin	(130-175) g/L	AC	4	50	8
Hemoglobin	(130-175) g/L	ACP	6	50	12
Erythrocyte	(4.3-5.8)×10¹² cells /L	AC	1	50	2
Erythrocyte	(4.3-5.8)×10¹² cells /L	ACP	7	50	14
Total protein	(65-85) g/L	AC	1	50	2
Total protein	(65-85) g/L	ACP	7	50	14
Albumin	(40-55) g/L	AC	1	50	2
Albumin	(40-55) g/L	ACP	3	50	6
Haematoblast	(125-350)× 10⁹ cells /L	AC	30	50	60
Haematoblast	(125-350)× 10⁹ cells /L	ACP	33	50	66
Aspartate aminotransfrase	(15-35) U /L	AC	33	50	66
Aspartate aminotransfrase	(15-35) U /L	ACP	32	50	64
Alanine aminotransfrase	(7-40) U /L	AC	49	50	98
Alanine aminotransfrase	(7-40) U /L	ACP	46	50	92
Total bilirubin	(3.4-17.1) μmol /L	AC	40	50	80
Total bilirubin	(3.4-17.1) μmol /L	ACP	37	50	74
Uric acid	(155-357) μmol /L	AC	35	50	70
Uric acid	(155-357) μmol /L	ACP	40	50	80
Creatinine	(58-84) μmol /L	AC	27	50	54
Creatinine	(58-84) μmol /L	ACP	36	50	72
Kalium	(3.5-5.3) mmol /L	AC	39	50	78
Kalium	(3.5-5.3) mmol /L	ACP	44	50	88
Natrium	(137-147) mmol /L	AC	38	50	76
Natrium	(137-147) mmol /L	ACP	40	50	80
Chlorinum	(99-110) mmol /L	AC	32	50	64
Chlorinum	(99-110) mmol /L	ACP	40	50	80

Open in a separate window

Het volledige studierapport: A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer gepubliceerd in CANCER is gratis in te zien.

Hier het abstract met referentielijst:

In the present study, our work showed that the probiotic combination of B. infantis, L. acidophilus, E. faecalis and B. cereus significantly enhanced the immunity of patients, reduced inflammation and was beneficial to restore the microbial diversity of patients who received gastrectomy. Therefore, the present randomised clinical trial illustrates the benefits of oral probiotics in the prevention of physiological and microbial disorders when provided to cancer patients after gastrectomy.

. 2019; 10(3): 568–576.

Published online 2019 Jan 1. doi: 10.7150/jca.29072

PMCID: PMC6360416

PMID: 30719153

A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer

Cihua Zheng,¹ Tingtao Chen,^2,^✉ Yuqing Wang,² Yuan Gao,² Yao Kong,² Zhaoxia Liu,³ and Xiaorong Deng^1,^✉

Author information Article notes Copyright and License information Disclaimer

Abstract

Gastrectomy has been widely used for the treatment of gastric cancer, and the severity of physiological and microbial disorders has greatly harmed the health of patients. In the present study, a probiotic combination containing Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis and Bacillus cereus was used to reduce the physiological disorders induced by gastrectomy via monitoring the blood index and microbial diversity using high-throughput sequencing. Our results indicated that the probiotic combination had significantly reduced the inflammation indexes (leukocyte) (p<0.05), while it markedly enhanced the immunity indexes (lymphocyte) and nutrition indexes (albumin and total protein) (p<0.05). In addition, gastric cancer had a strong influence on the microbial diversity of the stomach via enhancing the number of pathogens of Streptococcus, Peptostreptococcus and Prevotella, and reducing the percentage of the probiotic Bifidobacterium. Although partial gastrectomy markedly changed intestinal microbial diversity, the taking of the probiotic combination greatly reduced the ratio of Firmicutes/Bacteroidetes compared with patients taking no probiotics at the phylum level. At the genus level, the probiotic combination significantly enhanced the numbers of the probiotic bacteria Bacteroides, Faecalibacterium and Akkermansia and lowered the richness of Streptococcus. Therefore, we concluded that the taking of the probiotic combination significantly enhances the immune response of patients and reduces the severity of inflammation through modification of gut microbiota.

Consent for publication

Written informed consent was obtained from all participants.

Go to:

References

1. Cancer UK. Stomach (gastric) cancer. Us National Cancer Institute; 2014. [Google Scholar]

2. Stewart B, Wild C. World cancer report 2014: International Agency for Research on Cancer. 2014.

3. Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med. 2013;16:358. [PubMed] [Google Scholar]

4. Cancer UK. Statistics and outlook for stomach cancer. 2014.

5. Pretz JL, Wo JY, Mamon HJ, Kachnic LA, Hong TS. Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer. Surg Oncol Clin N Am. 2013;22:511–24. [PubMed] [Google Scholar]

6. Meza-Junco J, Au HJ, Sawyer MB. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Management & Research. 2011;3:57. [PMC free article] [PubMed] [Google Scholar]

7. Antoniou SA, Antoniou GA, Koch OO, Pointner R, Granderath FA. Laparoscopic colorectal surgery confers lower mortality in the elderly: a systematic review and meta-analysis of 66,483 patients. Surg Endosc. 2015;29:322–33. [PubMed] [Google Scholar]

8. Tegels JJ, Hulsewé KW, Sosef MN, Stoot JH. Morbidity and mortality after total gastrectomy for gastric malignancy: Do not forget about geriatric frailty and nutrition. Surgery. 2015;157:406–7. [PubMed] [Google Scholar]

9. Portanova M. Successful enteral nutrition in the treatment of esophagojejunal fistula after total gastrectomy in gastric cancer patients. World J Surg Oncol. 2010;8:71. [PMC free article] [PubMed] [Google Scholar]

10. Nozoe T, Anai H, Sugimachi K. Usefulness of reconstruction with jejunal pouch in total gastrectomy for gastric cancer in early improvement of nutritional condition. Am J Surg. 2001;181:274–8. [PubMed] [Google Scholar]

11. Biragyn A, Ferrucci L. Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging. Lancet Oncol. 2018;19:e295–e304. [PMC free article] [PubMed] [Google Scholar]

12. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361:k2179. [PMC free article] [PubMed] [Google Scholar]

13. Lombardi VC, Meirleir KLD, Subramanian K, Nutritional Modulation of the Intestinal Microbiota; Future Opportunities for the Prevention and Treatment of Neuroimmune and Neuroinflammatory Disease ☆. Macromol Biosci; 2018. [PMC free article] [PubMed] [Google Scholar]

14. Zhao X, Chen T, Meng F. et al. Therapeutic effect of herb residue fermentation supernatant on spleen-deficient mice. Mol Med Rep. 2018;17:2764–70. [PubMed] [Google Scholar]

15. Chen T, Tian P, Huang Z, Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1. Appl Microbiol Biot; 2018. pp. 1–11. [PubMed] [Google Scholar]

16. Chen H, Luo T, Chen T, Wang G. Seminal bacterial composition in patients with obstructive and non-obstructive azoospermia. Experimental & Therapeutic Medicine. 2018;15:2884–90. [PMC free article] [PubMed] [Google Scholar]

17. Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. Cancer cell; 2018. [PubMed] [Google Scholar]

18. Hersoug LG, Møller P, Loft S. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity. Nutr Res Rev; 2018. p. 1. [PubMed] [Google Scholar]

19. Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer cell. 2018;33:570–80. [PMC free article] [PubMed] [Google Scholar]

20. Crusell MKW, Hansen TH, Nielsen T. et al. Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum. Microbiome. 2018;6:89. [PMC free article] [PubMed] [Google Scholar]

21. Cirstea M, Radisavljevic N, Finlay B. Good Bug, Bad Bug: Breaking through Microbial Stereotypes. Cell Host Microbe. 2018;23:10–3. [PubMed] [Google Scholar]

22. Yu X, Wu X, Qiu L. et al. Analysis of the intestinal microbial community structure of healthy and long-living elderly residents in Gaotian Village of Liuyang City. Appl Microbiol Biot. 2015;99:9085–95. [PubMed] [Google Scholar]

23. Meng F, Chen T, Wang X, Evaluation of the accuracy and sensitivity of high-throughput sequencing technology using known microbiota. Mol Med Rep; 2017. [PubMed] [Google Scholar]

24. Xin F, Xin W, Yang S, Evaluation of the Microbial Diversity in Amyotrophic Lateral Sclerosis Using High-Throughput Sequencing. Front Microbiol; 2016. p. 7. [PMC free article] [PubMed] [Google Scholar]

25. Xu J, Lian FM, Zhao LH. et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. Isme J. 2015;9:552–62. [PMC free article] [PubMed] [Google Scholar]

26. Bolger A, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20. [PMC free article] [PubMed] [Google Scholar]

27. Edgar R. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10:996–8. [PubMed] [Google Scholar]

28. Steege HT. Measuring Biological Diversity. Environ Ecol Stat. 2004;1:95–103. [Google Scholar]

29. Caporaso JG, Kuczynski J, Stombaugh J. et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335. [PMC free article] [PubMed] [Google Scholar]

30. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell. 1990;62:3–6. [PubMed] [Google Scholar]

31. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell. 1994;76:241–51. [PubMed] [Google Scholar]

32. Zhou L, Sonnenberg GF. Essential immunologic orchestrators of intestinal homeostasis. Science Immunology. 2018;3:eaao1605. [PMC free article] [PubMed] [Google Scholar]

33. Postler TS, Ghosh S. Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System. Cell Metab. 2017;26:110. [PMC free article] [PubMed] [Google Scholar]

34. Kramer CD, Genco CA. Microbiota, Immune Subversion, and Chronic Inflammation. Front Immunol; 2017. p. 8. [PMC free article] [PubMed] [Google Scholar]

35. Hand TW, Vujkoviccvijin I, Ridaura VK, Belkaid Y. Linking the microbiota, chronic disease and the immune system. Trends Endocrin Met. 2016;27:831. [PMC free article] [PubMed] [Google Scholar]

36. Dwivedi M, Ansarullah, Radichev I, Kemp EH. Alteration of Immune-Mechanisms by Human Microbiota and Development and Prevention of Human Diseases. J Immunol Res. 2017;2017:1–2. [PMC free article] [PubMed] [Google Scholar]

37. Forbes JD, Domselaar GV, Bernstein CN. The Gut Microbiota in Immune-Mediated Inflammatory Diseases. Front Microbiol; 2016. p. 7. [PMC free article] [PubMed] [Google Scholar]

38. World Health Organization. Dept. of Immunization V, Biologicals. Initiative for Vaccine Research: 2004-2005 Strategic Plan. Oral Surg Oral Med O. 2003;95:206–7. [Google Scholar]

39. Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2017;106:171–81. [PubMed] [Google Scholar]

probiotica, maagkanker, operatie, darmflora, lichamelijke klachten, placebo gecontroleerde gerandomiseerde studie